ClinicalTrials.gg
CompletedNCT02482935Updated Jan 4, 2019Results posted

A Study of Abemaciclib (LY2835219) in Healthy Participants With and Without Food

A Phase 1 interventional study of Abemaciclib in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-04.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to evaluate the amount of abemaciclib that reaches the blood stream and how long the body takes to get rid of it when given with and without food. In addition, the safety and tolerability of the study drug will be evaluated. Information about any side effects that may occur will also be collected. The study will last about 43 days for each participant, not including screening.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy sterile males or surgically sterile or females
  • Have a (BMI) of 18 to 32 kilogram per meter square (kg/m\^2), inclusive

Exclusion criteria

Exclusion Criteria:

  • Participated in a clinical trial involving product within 30 days
  • Have known allergies to abemaciclib, related compounds or any components of the formulation, or history of significant atopy
  • Have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have an abnormal blood pressure
  • Show evidence of (HIV), or
  • Have donated blood of more than 500 milliliter (mL) within the last month
  • Have an average weekly alcohol intake that exceeds 21 units per week (males up to age 65) and 14 units per week (males over 65 and females), or are unwilling to stop alcohol consumption 48 hours prior to each admission until collection of the last PK sample in each period
  • Are unwilling to refrain from consuming xanthine-containing food and drink from 48 hours prior to admission until collection of the last pharmacokinetic (PK) sample in each period
  • Are currently or have been smokers or users of tobacco or nicotine replacement products within the 6 months prior to admission or have a positive urine cotinine test
  • Are unwilling to comply with the dietary requirements/restrictions during the study: Consume only the meals provided during the inpatient stays and refrain from eating any food or drinking any beverages containing grapefruit, grapefruit juice, grapefruit-containing products, Seville oranges, star fruit or star fruit juice, pomelo, or commercial apple juice or orange juice for at least 2 weeks prior to the first dose until the final PK sample is collected
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Abemaciclib High Fat Meal

    Abemaciclib capsules administered once orally in the fed state.

    Drug: Abemaciclib

  • Experimental
    Abemaciclib Fasted

    Abemaciclib capsules administered once orally in the fasted state.

    Drug: Abemaciclib

Interventions

  • Administered orally

    Also known as: LY2835219

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-inf]) for Both Fed and Fasted Periods for Abemaciclib and Major Metabolites

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose in Each Period

  2. Pharmacokinetics: Maximum Concentration (Cmax) for Both Fed and Fasted Periods for Abemaciclib and Major Metabolites

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose in Each Period

Secondary outcomes

  1. Pharmacokinetics: Time to Maximum Concentration (Tmax) for Both Fed and Fasted Periods for Abemaciclib and Major Metabolites

    Time frame: Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose in Each Period

07

Results

Posted Aug 3, 2018

Participant flow

Period 1
Participant flow — Period 1
MilestoneAbemaciclib Fasted/FedAbemaciclib Fed/Fasted
Started1515
Received abemaciclib1515
Washout1515
Completed1415
Not completed10
Withdrew: Withdrawal by subject10
Period 2
Participant flow — Period 2
MilestoneAbemaciclib Fasted/FedAbemaciclib Fed/Fasted
Started1415
Received abemaciclib1415
Follow-up1415
Completed1415
Not completed00

Outcome measures

PrimaryPharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-inf]) for Both Fed and Fasted Periods for Abemaciclib and Major Metabolites
Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose in Each Period
Reported as:
Geometric mean · nanograms x hours/mililiters (ng·h/mL)
Pharmacokinetics: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC [0-inf]) for Both Fed and Fasted Periods for Abemaciclib and Major Metabolites
nanograms x hours/mililiters (ng·h/mL)Abemaciclib FastedAbemaciclib Fed
Abemaciclib3940 ± 344950 ± 42
LSN28395671630 ± 271910 ± 28
LSN31067263180 ± 253410 ± 28
PrimaryPharmacokinetics: Maximum Concentration (Cmax) for Both Fed and Fasted Periods for Abemaciclib and Major Metabolites
Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose in Each Period
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Maximum Concentration (Cmax) for Both Fed and Fasted Periods for Abemaciclib and Major Metabolites
ng/mLAbemaciclib FastedAbemaciclib Fed
Abemaciclib116 ± 36159 ± 38
LSN283956733.4 ± 3641.4 ± 29
LSN310672655.7 ± 3161.0 ± 29
SecondaryPharmacokinetics: Time to Maximum Concentration (Tmax) for Both Fed and Fasted Periods for Abemaciclib and Major Metabolites
Time frame:
Day 1: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 144, 168, and 192 Hours Postdose in Each Period
Reported as:
Median · hours
Pharmacokinetics: Time to Maximum Concentration (Tmax) for Both Fed and Fasted Periods for Abemaciclib and Major Metabolites
hoursAbemaciclib FastedAbemaciclib Fed
Abemaciclib8.00 (6.00 to 12.00)8.00 (6.00 to 12.00)
LSN28395676.00 (3.00 to 12.00)6.00 (4.00 to 12.00)
LSN31067268.02 (6.00 to 24.02)10.00 (6.00 to 24.03)

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abemaciclib Fasted—0/30 (0%)4/30 (13.3%)
Abemaciclib Fed—0/29 (0%)2/29 (6.9%)
Most frequent other events
Most frequent other events
EventAbemaciclib FastedAbemaciclib Fed
NauseaGastrointestinal disorders3/300/29
HeadacheNervous system disorders1/302/29
VomitingGastrointestinal disorders2/300/29

Baseline characteristics

All participants who received abemaciclib.

Age, Continuous
Age, Continuous(years)Abemaciclib
Mean49.1 ± 11.5
Sex: Female, Male
Sex: Female, Male(Participants)Abemaciclib
Female11
Male19
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Abemaciclib
Hispanic or Latino9
Not Hispanic or Latino21
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abemaciclib
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American7
White22
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Abemaciclib
United States30
08

Study locations

2 sites
  • Covance Clinical Research Unit
    Daytona Beach, Florida 32117, United States
  • Covance Clinical Research Unit
    Dallas, Texas 75247, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2015, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 2 years 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2015
First posted
Jun 26, 2015
Start
Jun 2015
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Aug 3, 2018
Last update
Jan 4, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02482935
Responsible party
Sponsor
First posted
Jun 26, 2015
Start date
Jun 2015
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Aug 3, 2018
Last update
Jan 4, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion